Claret Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Claret Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Sell	3,913 -236	-6%	-$12.9K	0.02%	407
2026 Q1	$234K	Hold	4,149	–	–	0.03%	274
2025 Q4	$247K	Sell	4,149 -9	-0.2%	-$490	0.03%	263
2025 Q3	$225K	Sell	4,158 -59	-1%	-$3.37K	0.03%	334
2025 Q2	$232K	Buy	+4,217	New	+$248K	0.03%	335

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Claret Asset Management's BMRN Position: Q2 2026 in Review

Claret Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 5.7% in Q2 2026, selling an estimated $12.9K and leaving 3,913 shares worth $224K. The position accounts for 0.02% of the portfolio, ranked #407.

Claret Asset Management first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $247K in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Claret Asset Management held 3,913 shares of BioMarin Pharmaceuticals worth $224K as of Q2 2026.
Claret Asset Management sold 236 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $12.9K.
BioMarin Pharmaceuticals made up 0.02% of Claret Asset Management's portfolio in Q2 2026, its #407 holding.
Claret Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
Claret Asset Management's BioMarin Pharmaceuticals position peaked at $247K in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Claret Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.